MBX Biosciences (MBX) Current Assets (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Current Assets data on file, last reported at $448.5 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 83.62% year-over-year to $448.5 million; the trailing twelve-month figure through Mar 2026 stood at $448.5 million (up 83.62% YoY), and the FY2025 full-year result was $381.5 million, up 42.75% from the prior year.
• Current Assets grew to $448.5 million in Q1 2026, from $381.5 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $448.5 million in Q1 2026 to a low of $83.5 million in Q4 2023.
• A 4-year average of $291.6 million and a median of $274.2 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets jumped 220.24% in 2024 and surged 41.37% in 2025, its largest moves.
• Tracing MBX's Current Assets over 4 years: stood at $83.5 million in 2023, then jumped by 220.24% to $267.3 million in 2024, then jumped by 42.75% to $381.5 million in 2025, then climbed by 17.56% to $448.5 million in 2026.
• Business Quant data shows MBX's Current Assets at $448.5 million in Q1 2026, $381.5 million in Q4 2025, and $397.5 million in Q3 2025.